Quantum BioPharma (QNTM, Financial) has entered into a partnership with a prominent pharmaceutical contract research organization to develop an Investigational New Drug (IND) application for its innovative compound, Lucid-21-302, targeting multiple sclerosis (MS). The agreement aims to secure approval from the U.S. Food and Drug Administration (FDA) to progress to a Phase 2 clinical trial for MS patients.
Lucid-21-302 is distinguished as a novel, non-immunomodulatory neuroprotective agent with a pioneering mechanism of action designed to address MS. As a patented New Chemical Entity, the compound has demonstrated efficacy in preclinical studies, showing potential to inhibit demyelination, a key driver of MS and other neurodegenerative disorders that result from the degradation of the protective myelin sheath around nerve fibers.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Quantum BioPharma Ltd (QNTM, Financial) is $169.00 with a high estimate of $169.00 and a low estimate of $169.00. The average target implies an upside of 1,278.47% from the current price of $12.26. More detailed estimate data can be found on the Quantum BioPharma Ltd (QNTM) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Quantum BioPharma Ltd's (QNTM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
